Skip to main content
. 2017 Oct 12;38(11):1501–1511. doi: 10.1038/aps.2017.124

Figure 2.

Figure 2

Gefitinib efficiently inhibits the M2-like polarization of macrophages induced by IL-13. (A) RAW 264.7 cells were treated with IL-13 (10 ng/mL) with or without gefitinib (0.62 μmol/L) for 72 h. The expression of the cell surface M2 marker CD206+ was analyzed by FACS analysis. (B and C) Bone marrow-derived macrophages (BMDMs) were treated with IL-13 (10 ng/mL) with or without different concentrations of gefitinib for 72 h. The percentages of F4/80+, CD206+ and CD163+ macrophages were analyzed by FACS analysis. The results are presented as the mean±SEM of triplicate determination. *P<0.05; **P<0.01.